arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2004-10-1-43-45arthyper-960Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESАнтагонисты кальция: принципы терапии в свете данных доказательных исследованийCalcium antagonists: principals of therapy in the light of evidence based studies dataМарцевичС. Ю.MarcevichM. U.noemail@neicon.ruГНИЦ профилактической медициныRussian Federation2004280220041014345Copyright © Марцевич С.Ю., 20042004Марцевич С.Ю.Marcevich M.U.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/960

Антагонисты кальция (AK) - группа препаратов, основным свойством которых является способность обратимо ингибировать ток Ca в клетку через так называемые медленные кальциевые каналы. По химической структуре AK делятся на две большие подгруппы - дигидропиридины (нифедипин, амлодипин, фелодипин и пр.) и недигидропиридины (верапамил и дилтиазем). Различают AK первого поколения (обычные таблетки короткой продолжительности действия) и AK второго поколения (специальные таблетки пролонгированного действия), последние не только более удобны в применении, но и более безопасны. Данные крупных рандомизированных исследований однозначно свидетельствуют о том, что AK благоприятно влияют на прогноз жизни больных с артериальной гипертонией, не отличаясь в целом по этому действию от других гипотензиных препаратов. Вместе с тем AK в большей степени, чем другие гипотензивные препараты, уменьшают риск мозгового инсульта, но в меньшей степени, чем другие гипотензивные препараты, уменьшают риск острого инфаркта миокарда и сердечной недостаточности.

Calcium antagonists (CA) are the group of drugs the main property of which are the ability to inhibit calcium influx through the so-called slow calcium channels. According to chemical structure, CA are divided into dihydropyridines (nifedipine, amlodipine, felodipine) and nondihydropyridines (verapamil and diltiazem). CA are also divided into first generation agents (conventional tablets) and second generation agents (long acting agents), the last are not only more convenient bat also more safe drugs. The data of large randomised trials confirm that CA have favorable effect on life prognosis during their regular administration to patients with arterial hypertension, this effect of CA is similar to that of other antihypertensive drugs (AHD). However, CA may be superior to other AHD in preventing stroke and inferior to other AHD in preventing myocardial infarction and congestive heart failure.

ReferencesReport of tbe Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised double-blindplacebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56: 400-13.Report of tbe Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised double-blindplacebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56: 400-13.Furberg CD, Psaty BM1 MeyerJV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-31-Furberg CD, Psaty BM1 MeyerJV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-31-Pahor M, Psaty B. Alderman M. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000; 356:1949-54-Pahor M, Psaty B. Alderman M. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000; 356:1949-54-Blood Pressure Lowering Treatment Trialists’ Collaboration, Effects of ACE-inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 200; 355-1955-64-Blood Pressure Lowering Treatment Trialists’ Collaboration, Effects of ACE-inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 200; 355-1955-64-Brotvn MJбPalmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment witb a long-acting caldum channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-72.Brotvn MJбPalmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment witb a long-acting caldum channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-72.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981 -97-The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981 -97-Kolloch RE. INVEST: Results of combined strategies to control blood pressure. Clin Cardiol2001; 24 (suppl V): V12-V13.Kolloch RE. INVEST: Results of combined strategies to control blood pressure. Clin Cardiol2001; 24 (suppl V): V12-V13.Psaty B, Lumley T1 Furberg C et al. Health outcomes associated witb various antihypertensive therapies used as first-line agents. JAMA 2003; 289- 2534-44.Psaty B, Lumley T1 Furberg C et al. Health outcomes associated witb various antihypertensive therapies used as first-line agents. JAMA 2003; 289- 2534-44.Opie L, Schall R Evidence-based evaluations of calcium channel blockersfor hypertension JAm Coll Cardiol 2002; 39:315-22.Opie L, Schall R Evidence-based evaluations of calcium channel blockersfor hypertension JAm Coll Cardiol 2002; 39:315-22.Staesssen J.Ji-Guang Wang, Thijs L. Calcium-cbannel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15: 85S-93S.Staesssen J.Ji-Guang Wang, Thijs L. Calcium-cbannel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15: 85S-93S.Staessen JA, Fagard R, Thijs L et аЦ for the Systolic Hypertension in Europe Trial Investigators. Randomised double-blind comparison of placebo and active treatmentfor older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64-Staessen JA, Fagard R, Thijs L et аЦ for the Systolic Hypertension in Europe Trial Investigators. Randomised double-blind comparison of placebo and active treatmentfor older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64-Guidelines Committee. 2003 European Sodety of Hypertension-European Society of Cardiology guidelinesfor tbe management of arterial hypertension.] Hypertension 2003; 21:1011-53.Guidelines Committee. 2003 European Sodety of Hypertension-European Society of Cardiology guidelinesfor tbe management of arterial hypertension.] Hypertension 2003; 21:1011-53.

The authors declare that there are no conflicts of interest present.